We’re determined to unlock the mysteries of tumor biology and the tumor microenvironment.
That means applying our scientific curiosity to tackling challenging tumor types in gastrointestinal (GI),
genitourinary (GU), and thoracic cancers, where there are unmet needs—driving us to transform cancer care for challenging cancers.
Our R&D team is leveraging our synergistic portfolio in immuno-oncology, DNA damage response (DDR), and oncogenic pathways, and focusing our scientific discovery and development to unleash the potential of promising approaches in cancer research.
Accelerating the development of current and next-generation immuno-oncology therapies that harness the patient's immune system to fight cancer
Pioneering research into the multiple pathways involved in DDR aims to both disrupt the tumor's ability to repair damage and to restore sensitivity to treatments
Exploring oncogenic pathways to expand use of existing and new targeted therapies to address more tumor types and oncogenic mutations
Our curiosity drives us to transform the standard of care for challenging cancers.
How do MET alterations drive oncogenesis in non-small cell lung cancer (NSCLC)? How do these alterations arise, and how do they impact patient prognosis? If you have patients with MET alterations, visit our website to learn more about testing options and additional information that can help inform treatment decisions for your patients with NSCLC.VISIT WEBSITE
Is the DNA damage response pathway a viable target for cancer therapy? This video discusses the key protein kinases implicated in DDR pathways and the potential implications of inhibition of these pathways in cancer.WATCH VIDEO